Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28527177 | 1.00 | DRD2 (0.45) | DRD2CA12CA1CA2CA9 | |
| SCHEMBL18989249 | 0.86 | MTNR1A (0.43) | CA12CA1CA2CA9MTNR1A | |
| SCHEMBL18989248 | 0.86 | MTNR1A (0.43) | CA12CA1CA2CA9MTNR1A | |
| SCHEMBL24936191 | 0.85 | KCNH2 (0.46) | DRD2CA12CA1CA2CA9 | |
| SCHEMBL1978348 | 0.83 | DRD2 (0.51) | DRD2CA12CA1CA2CA9 | |
| SCHEMBL28527175 | 0.81 | TDP1 (0.39) | MTNR1AMTNR1BTDP1LMNAMAPT | |
| SCHEMBL24936245 | 0.80 | STK17B (0.41) | DRD2CA12CA1CA2CA9 | |
| SCHEMBL3514820 | 0.79 | MTNR1A (0.61) | DRD2CA12CA1CA2CA9 | |
| SCHEMBL19007377 | 0.78 | DRD2 (0.46) | DRD2CA12CA1CA2CA9 | |
| SCHEMBL11538773 | 0.78 | TDP1 (0.60) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349948-B | 5- (5- (2- (3-aminopropoxy) -6-methoxyphenyl) -1H-pyrazol-3-ylamino) pyrazine-2-carbonitrile (S) -lactate monohydrate | 伊莱利利公司 | 2021-02-23 | — | — | CN | disclosed |
| EP-3389660-B1 | COMBINATION THERAPY FOR CANCER | LILLY CO ELI (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10189818-B2 | 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitfile (S)-lactate monohydrate | ELI LILLY AND COMPANY (US) | 2019-01-29 | — | — | US | disclosed |
| WO-2017105982-A1 | COMBINATION THERAPY FOR CANCER | ELI LILLY AND COMPANY (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189818-B2 | 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitfile (S)-lactate monohydrate | CHEK2, CHEK1, LDHA | DRD2 4859/4885CA12 1638/4885CA1 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.